P. Schygiel

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Khalid Yusoff, Frederick M. Costello, Martin O'Donnell, 2017, Lancet.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

Mehrad Amin Eskandari, J. F. Tinto, A. Capucci, 2018, Indian heart journal.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

P. Ponikowski, S. Solomon, M. Pfeffer, 2013, European journal of heart failure.

Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study

K. L. Bansal, J. J. Huang, Michael A. Rodriguez, 2018, The Lancet.

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

Michael A. Rodriguez, M. S. Lee, S. W. Park, 2019, Journal of the American Heart Association.

Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.

K. L. Bansal, J. J. Huang, Michael A. Rodriguez, 2018, Lancet.

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

Michael A. Rodriguez, Y. Y. Liu, J. F. Tinto, 2019, Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.